Hepatitis C drugs multiply effect of COVID-19 antiviral Remdesivir
- Details
- Category: Research
Published this week in Cell Reports, this finding - from Gaetano Montelione, a professor of chemistry and chemical biology at Rensselaer Polytechnic Institute, and his collaborators at the Icahn School of Medicine at Mount Sinai and the University of Texas at Austin - raises the potential for repurposing available drugs as COVID-19 antivirals in cases where a vaccine isn't practical or effective.
How COVID-19 impacted UK healthcare
- Details
- Category: Research
A new study published today looks at the extent to which people managed to access NHS healthcare in April 2020, and as lockdown restrictions eased.
Artificial intelligence model predicts which key of the immune system opens the locks of coronavirus
- Details
- Category: Research
Updated results on coronavirus vaccination effectiveness
- Details
- Category: Research
Differing immune responses discovered in asymptomatic cases vs those with severe COVID-19
- Details
- Category: Research
Researchers from the Wellcome Sanger Institute, Newcastle University, University College London, University of Cambridge, EMBL's European Bioinformatics Institute (EMBL-EBI) and their collaborators within the Human Cell Atlas initiative, found raised levels of specific immune cells in asymptomatic people.
Patients who are obese or overweight are at risk for a more severe course of COVID-19
- Details
- Category: Research
New COVID-19 vaccine may offer broad protection from coronaviruses
- Details
- Category: Research
Vaccines created by UVA Health's Steven L. Zeichner, MD, PhD, and Virginia Tech's Xiang-Jin Meng, MD, PhD, prevented pigs from being becoming ill with a pig model coronavirus, porcine epidemic diarrhea virus (PEDV).
More Pharma News ...
- SARS-CoV-2: New findings on the persistence of neutralizing antibodies
- Massive fragment screen points way to new SARS-CoV-2 inhibitors
- B.1.1.7. variant more transmissible, does not increase severity, Lancet studies suggest
- COVID-19 causes 'unexpected' cellular response in the lungs
- Clinical trial completion rates decline during COVID-19 pandemic
- Study identifies possible COVID-19 drugs - including several that are FDA-approved
- COVID-19 convalescent plasma with greater antibody levels is safe and shows promise